Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC)

Daclatasvir-Based Therapy Safety Surveillance in Chinese Patients With Chronic Hepatitis C

Study is a non-interventional, prospective, multicenter post marketing surveillance study to determine the safety of daclatasvir based therapy

Inclusion Criteria:

• Participants 18 years of age and older
• Participants with Chronic Hepatitis C virus (CHC) who are eligible for treatment with branded DCV-based therapy as indicated in the locally approved label

Exclusion Criteria:

• Participants under the age of 18

Other protocol defined inclusion/exclusion criteria could apply